Evidence map›Paper›PMID 10931135›Full record

ArticleClinical and experimental immunology2000

The C5a receptor is expressed by human renal proximal tubular epithelial cells.

R Zahedi, M Braun, R A Wetsel, B H Ault, A Khan, T R Welch, M Frenzke, A E Davis

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Complement activation in progressive renal disease.World journal of nephrology · 2015
    Review
  12. Review
  13. C3a and C5a promote renal ischemia-reperfusion injury.Journal of the American Society of Nephrology : JASN · 2012
    Article
  14. Article
  15. Article
  16. Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2009
    Article
  17. Article
  18. Review
  19. Review
  20. Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2005
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

R ZahediThe Center for Blood Research, Boston, MA, Immune Cell Interaction Unit, Mucosal Immunity Section, Laboratory of Clinical Investigation, NIAID, Bethesda, MD, USA.
M Braun
R A Wetsel
B H Ault
A Khan
T R Welch
M Frenzke
A E Davis
Cincinnati Children's Hospital Medical Center · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USNational Institutes of Health · USThe University of Texas Health Science Center at Houston · USUniversity of Tennessee Health Science Center · USWashington University in St. Louis · US

Funding

MURINE COMPLEMENT C5 DEFICIENCY--MOLECULAR BASISR01AI025011 · NIAID · WASHINGTON UNIVERSITY · PI WETSEL, RICK A. · 1987 to 2017
$4.6M
C1 INHIBITOR GENE AND HEREDITARY ANGIONEUROTIC EDEMAR37HD022082 · NICHD · IMMUNE DISEASE INSTITUTE, INC. · PI DAVIS, ALVIN E · 1999 to 2008
$3.9M
REGULATION OF C1 INHIBITOR SYNTHESISR01HD033727 · NICHD · IMMUNE DISEASE INSTITUTE, INC. · PI DAVIS, ALVIN E · 1996 to 2004
$1.5M
THE C1 INHIBITOR GENE AND HEREDITARY ANGIONEUROTIC EDEMAR01HD022082 · NICHD · CHILDREN'S HOSPITAL MED CTR (CINCINNATI) · PI DAVIS, ALVIN E · 1987 to 1998
–
COMPLEMENT C5 AND THE C5A-RECEPTOR: MOLECULAR GENETICSR55AI025011 · NIAID · WASHINGTON UNIVERSITY · PI WETSEL, RICK A. · 1991 to 1991
–
NIAID NIH HHS AI25011NIAID NIH HHS R01 AI025011NICHD NIH HHS HD22082NICHD NIH HHS HD33727NICHD NIH HHS R01 HD033727NICHD NIH HHS R37 HD022082
6 · The paper itself

Abstract

The C5a receptor is expressed by a variety of cell types. These studies demonstrate by immunohistochemistry that the receptor is present on the surface of proximal and distal tubular epithelial cells from normal kidney. In addition, the receptor was detected on transitional epithelial cells of the ureter and bladder. Primary proximal tubular cultures and a proximal tubular cell line both also expressed the C5a receptor, as demonstrated by immunofluorescence and by FACS analysis. The presence of mRNA encoding the receptor was confirmed by reverse transcriptase-polymerase chain reaction analysis. As opposed to its effect on glomerular mesangial cells, the receptor did not mediate a proliferative response by the proximal tubular cells. C5a also did not enhance the synthesis/secretion of transforming growth factor-beta 1, monocyte chemoattractant protein-1, platelet-derived growth factor-AB or tumour necrosis factor-alpha by cultured proximal tubular cells. Therefore, although the C5a receptor clearly is expressed by proximal tubular cells, clarification of its functional relevance on this cell type awaits further studies.

Indexed as

Antigens, CDCell DivisionCells, CulturedCytokinesEnzyme-Linked Immunosorbent AssayEpithelial CellsFlow CytometryFluorescent Antibody Technique, IndirectGlomerular MesangiumGrowth SubstancesHumansKidney Tubules, DistalKidney Tubules, ProximalMuscle, SmoothReceptor, Anaphylatoxin C5aReceptors, ComplementAntigens, CDCytokinesGrowth SubstancesReceptor, Anaphylatoxin C5aReceptors, ComplementRNA, MessengerRNA, Neoplasm

Identifiers

PMID10931135
PMCPMC1905711
OpenAlexW1979186736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.